Nanobiotix SA (FR:NANO)
:NANO
Top Page
Nanobiotix
(NANO)
Select Model
Select Model
Rating:52Neutral
Price Target:
€19.50
▼(-26.55% Downside)
Action:ReiteratedDate:11/11/25
Nanobiotix's overall score of 52 reflects significant financial challenges as the primary drag, with declining revenue, deepening losses, and negative equity signaling high risk. Positive technical momentum, with the stock price above key moving averages, provides some upside, while valuation concerns due to negative P/E add caution. Financial performance remains the most impactful factor.
Positive Factors
Innovative Product Pipeline
Nanobiotix's focus on nanotechnology for cancer treatment positions it as a leader in innovative oncology solutions, potentially improving patient outcomes and addressing unmet medical needs.
Negative Factors
Negative Profitability
Ongoing negative profitability and high leverage indicate financial instability, which could limit Nanobiotix's ability to invest in growth and sustain operations long-term.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Product Pipeline
Nanobiotix's focus on nanotechnology for cancer treatment positions it as a leader in innovative oncology solutions, potentially improving patient outcomes and addressing unmet medical needs.
Read all positive factors
Nanobiotix (NANO) vs. iShares MSCI France ETF (EWQ)
Market Cap
€1.31B
Dividend YieldN/A
Average Volume (3M)654.19K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,401,120
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-2.17
Price to Sales (P/S)-12.30
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.00Price Target Upside-13.37% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.28
Revenue Forecast (FY)€36.63M
Nanobiotix Business Overview & Revenue Model
Company Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treat...
How the Company Makes Money
Nanobiotix generates revenue primarily through the development and commercialization of its lead product, NBTXR3, which is in advanced clinical trials for treating several types of cancer. The company's revenue model includes potential milestone p...
Nanobiotix Earnings Call Summary
Earnings Call Date:Apr 02, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Apr 28, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with strong collaborations, especially with JNJ, advancements in clinical trials, and financial strategies to ensure sustainability. Despite financial lowlights such as negative revenue impacts and increased net loss, the strategic developments and pipeline progress suggest a promising future.Positive Updates
Strong Partnership with Johnson & Johnson
Nanobiotix has made significant progress with its collaboration with JNJ, which includes a $2.6 billion agreement with potential royalties. The collaboration is expanding into different indications such as lung cancer and head and neck cancer, potentially addressing over 100,000 patients and a $10 billion market in the US and EU5.
Negative Updates
Negative Revenue Impact
Nanobiotix reported negative revenue of €7.2 million for 2024 due to the transfer of the NANORAY-312 study sponsorship to JNJ, which led to a negative €19.3 million revenue impact. This was a non-cash item but affected financial results.
Read all updates
Q4-2024 Updates
Positive
Negative
Strong Partnership with Johnson & Johnson
Nanobiotix has made significant progress with its collaboration with JNJ, which includes a $2.6 billion agreement with potential royalties. The collaboration is expanding into different indications such as lung cancer and head and neck cancer, potentially addressing over 100,000 patients and a $10 billion market in the US and EU5.
Read all positive updates
Company Guidance
In the recent conference call, Nanobiotix provided comprehensive guidance on its financial and operational achievements for the fiscal year 2024, along with future projections. The company highlighted its collaboration with Johnson & Johnson, which involves a $2.6 billion plus royalties agreement, focusing on NBTXR3, now branded as JNJ-1900, targeting lung and head and neck cancers. This collaboration alone could potentially address over 100,000 patients in the U.S. and EU5, translating into a $10 billion market opportunity. Nanobiotix also launched its Curadigm platform, a first-in-class product poised to address multiple therapeutic areas. Financially, the company received a $20 million milestone payment in 2024 related to the NANORAY-312 trial and has extended its cash runway to mid-2026, with plans to explore nondilutive financing options to potentially extend this to 2027. The fiscal year concluded with a net loss increase of 72% to €68.1 million, primarily due to a onetime negative revenue impact from the transfer of study sponsorship to JNJ, which is a noncash item. The company ended 2024 with €49.7 million in cash and cash equivalents, compared to €75.3 million in the previous year.Nanobiotix Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.74M | -11.61M | 30.06M | 4.78M | 10.00K | 50.00K |
| Gross Profit | 5.74M | -11.61M | 30.06M | 3.28M | 2.65M | 2.33M |
| EBITDA | -43.33M | -61.62M | -30.09M | -53.78M | -45.60M | -31.49M |
| Net Income | -51.64M | -68.13M | -39.70M | -57.04M | -47.00M | -33.59M |
Balance Sheet | ||||||
| Total Assets | 45.17M | 67.42M | 93.90M | 59.77M | 101.67M | 133.93M |
| Cash, Cash Equivalents and Short-Term Investments | 28.82M | 49.74M | 75.28M | 41.39M | 83.92M | 119.15M |
| Total Debt | 51.24M | 50.90M | 50.56M | 53.17M | 46.02M | 48.98M |
| Total Liabilities | 114.13M | 133.12M | 95.74M | 86.81M | 74.98M | 63.56M |
| Stockholders Equity | -68.95M | -65.70M | -1.84M | -27.05M | 26.69M | 70.36M |
Cash Flow | ||||||
| Free Cash Flow | -31.64M | -20.40M | -12.81M | -38.11M | -31.24M | -28.34M |
| Operating Cash Flow | -31.13M | -19.55M | -12.48M | -38.02M | -31.00M | -28.24M |
| Investing Cash Flow | -617.00K | -955.00K | -349.00K | 138.00K | -242.00K | -112.00K |
| Financing Cash Flow | -5.31M | -5.13M | 46.77M | -5.65M | -4.05M | 111.77M |
Nanobiotix Technical Analysis
Positive
26.55
Price Trends
22.82
Positive
20.58
Positive
15.11
Positive
Market Momentum
0.96
Positive
52.17
Neutral
24.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:NANO, the sentiment is Positive. The current price of 26.55 is below the 20-day moving average (MA) of 27.85, above the 50-day MA of 22.82, and above the 200-day MA of 15.11, indicating a neutral trend. The MACD of 0.96 indicates Positive momentum. The RSI at 52.17 is Neutral, neither overbought nor oversold. The STOCH value of 24.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:NANO.
Nanobiotix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | €423.91M | -4.08 | -63.70% | ― | -45.41% | -273.69% | |
53 Neutral | €7.51B | -24.91 | ― | ― | ― | 18.52% | |
52 Neutral | €1.31B | -9.10 | ― | ― | ― | ― | |
52 Neutral | €982.37M | -1.44 | -241.12% | ― | ― | 3.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | €67.65M | -1.87 | -52.76% | ― | -96.92% | -175.84% | |
44 Neutral | €101.63M | -2.91 | -658.91% | ― | -75.86% | -30.54% |
* Healthcare Sector Average
FR:NANO
Nanobiotix
27.05
23.68
702.67%
FR:GNFT
Genfit
8.50
5.15
153.73%
FR:IPH
Innate Pharma SA
1.08
-0.79
-42.19%
FR:ABVX
Abivax SA
94.80
88.56
1419.23%
FR:DBV
DBV Technologies
3.53
2.75
351.98%
FR:OSE
OSE Immunotherapeutics SA
3.02
-3.13
-50.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.